Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Up 50.0% in September

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling 2,400 shares, an increase of 50.0% from the August 31st total of 1,600 shares. Based on an average daily volume of 62,800 shares, the short-interest ratio is currently 0.0 days.

Enzon Pharmaceuticals Price Performance

Shares of ENZN stock opened at $0.12 on Friday. The company has a market cap of $8.91 million, a price-to-earnings ratio of 12.00 and a beta of 0.51. The stock’s fifty day moving average price is $0.15 and its 200 day moving average price is $0.13. Enzon Pharmaceuticals has a 1-year low of $0.06 and a 1-year high of $0.24.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.